MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Merck & Co., Inc. is still a pharmaceutical standout, even after Goldman Sachs adjusted its market outlook. The firm revised ...

Merck & Co., Inc. (NYSE:MRK) is one of the top cheap pharmaceutical stocks to buy now. Goldman Sachs analyst Asad Haider ...

Of the companies that reported their results last week, 18 beat analysts’ earnings forecasts, while 3 missed. On the revenue ...

The global pharmaceutical sector is under increasing pressure as rising trade tensions drive countries to introduce new ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed.

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

In many ways, despite what RFK Jr. and Rep. Paul Gosar claim, the Vaccine Injury Compensation Program is more friendly to ...

Doctors at NIH discovered that a typically harmless strain of skin HPV directly caused 40 skin cancer lesions in a ...

Doctors at the National Institutes of Health have discovered a new cause of skin cancer, according to a report in the New ...